Effect of multiple doses of AZD6280 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2) - CYP

Study identifier:D0850C00015

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I open-labeled, fixed sequence study to determine the effect of multiple doses of AZD6280 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2)

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6280, Midazolam, Caffeine

Sex

Male

Actual Enrollment

24

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Jan 2009
Primary Completion Date: -
Study Completion Date: 01 Mar 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria